Tahamiler Rauf, Saritzali Gkioukxel, Canakcioglu Salih
Department of Otolaryngology, University of Istanbul, Cerrahpasa Medical School, Istanbul, Turkey.
Laryngoscope. 2007 Jun;117(6):965-9. doi: 10.1097/MLG.0b013e31804f8141.
Sublingual immunotherapy has a documented clinical efficacy, but only a few long-term studies have been performed in people with perennial rhinitis.
The purpose of this study was to evaluate the long-term efficacy of sublingual immunotherapy.
One hundred thirty-seven patients with allergies to house dust mites were treated with sublingual house dust-mite-specific immunotherapy for 2 or 3 years and were also observed for 3 years after discontinuation of the treatment. The patients were divided into 2 groups: group A (67 patients) received active treatment for 2 years and then 1 year for placebo, and group B (70 patients) received active treatment for 3 years. The success of the treatment was evaluated with the symptom score, skin prick test results, and the nasal allergen challenge score.
According to our study results, we found a greater improvement in the 3 years of sublingual immunotherapy compared with the 2 years of sublingual immunotherapy when we looked at the comparative results of the total 6 years.
We suggest 3 years of sublingual immunotherapy for patients with perennial allergic rhinitis who require immunotherapy and do not accept the subcutaneous route of allergen administration.
舌下免疫疗法已被证明具有临床疗效，但针对常年性鼻炎患者的长期研究较少。
本研究旨在评估舌下免疫疗法的长期疗效。
137名对屋尘螨过敏的患者接受了2年或3年的舌下屋尘螨特异性免疫疗法治疗，并在治疗停止后又观察了3年。患者被分为两组：A组（67名患者）接受2年的积极治疗，然后1年的安慰剂治疗；B组（70名患者）接受3年的积极治疗。通过症状评分、皮肤点刺试验结果和鼻过敏原激发试验评分来评估治疗的成功与否。
根据我们的研究结果，在观察6年的比较结果时，我们发现与2年的舌下免疫疗法相比，3年的舌下免疫疗法有更大的改善。
对于需要免疫疗法且不接受皮下过敏原给药途径的常年性变应性鼻炎患者，我们建议进行3年的舌下免疫疗法。
Zotero 插件